Triveni Bio CEO Vishal Patel and CSO Jennifer Dovey

Triveni Bio launch­es with $92M Se­ries A to fund eczema an­ti­body treat­ment

Triveni Bio has raised $92 mil­lion in a Se­ries A fi­nanc­ing round as it aims to move its atopic der­mati­tis an­ti­body in­to the clin­ic.

At­las Ven­ture and Cor­morant As­set Man­age­ment led the round, with Mass­a­chu­setts-based Triveni aim­ing to move TRIV-509 in­to the clin­ic in 2025 and a Phase IIa tri­al in atopic der­mati­tis in 2027. It al­so ex­pects to nom­i­nate two oth­er an­ti­body can­di­dates in 2024 that fo­cus on oth­er im­muno­log­i­cal and in­flam­ma­to­ry dis­or­ders. The com­pa­ny’s cash run­way is now set to last in­to 2027.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.